Vasculitis and biologic infusion therapies: Implications for nursing

Journal of Infusion Nursing

Volumn 29, Issue 5, 2006, Pages 272-282

  Sejismundo, Lourdes P ^a  

^a Johns Hopkins Vasculitis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALENDRONIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CD20 ANTIGEN; CHIMERIC ANTIBODY; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; ESOMEPRAZOLE; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NITROGEN; PREDNISONE; PROTON PUMP INHIBITOR; RANITIDINE; RITUXIMAB; STEROID; THIOPURINE METHYLTRANSFERASE; UNINDEXED DRUG; UREA; VITAMIN D;

ABORTION; ACNE; ALOPECIA; AVASCULAR NECROSIS; BONE DISEASE; BONE MARROW SUPPRESSION; BONE NECROSIS; CANCER; CAPILLARY RESISTANCE; CATARACT; CUSHINGOID SYNDROME; CYTOPENIA; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MECHANISM; DRUG TREATMENT FAILURE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; GLUCOSE INTOLERANCE; HEALTH CARE PERSONNEL; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INFECTION; INFECTION SENSITIVITY; INFERTILITY; INSOMNIA; LEG SWELLING; LIVER DISEASE; LYMPHOMA; MOOD CHANGE; MOUTH ULCER; NURSING CARE; OBESITY; OFF LABEL DRUG USE; OSTEOPOROSIS; OUTPATIENT CARE; PARESTHESIA; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; STRIA; TINNITUS; URTICARIA; VASCULITIS; WEGENER GRANULOMATOSIS; WEIGHT GAIN;

EID: 33750046348     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200609000-00006     Document Type: Review

References (20)

1. Langford CA, Sneller MC. Biologic therapies in the vasculitides. Curr Opin Rheumatol. 2003;15(1):3-10.
2. Stone JH. Targeted therapies in systemic vasculitis. Cleve Clin J Med. 2002;69(Suppl 2):124-128.
3. Levine SM, Stone JH. New approaches to treatment in systemic vasculitis: biological therapies. Best Pract Res Clin Rheumatol. 2001;15(2):315-333.
4. Imboden J, Hellmann DB, Stone JH, eds. Current Rheumatology Diagnosis & Treatment. 1st ed. New York: Lange Medical Books/McGraw-Hill; 2004:231-241, 248-255, 273-277, 281-285.
5. Saleh A, Stone JH. Classification and diagnostic criteria in systemic vasculitis. Best Pract Res Clin Rheumatol. 2004:1-13.
6. Wung PK, Holbrook JT, Hoffman GS, et al, for the WGET Research Group. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005;118(12):1416.
7. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(1):262-268.
8. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(12):1230-1233.
9. Koukoulaki M, Abeygunasekara SC, Smith KG, Jayne DR. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant. 2005;20(1):213-216.
10. Maureen BP, et al. Stedman's Medical Dictionary. 27th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2000.
11. Stone JH, Hoffman GS, Merkel PA, et al, and the International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum. 2001;44(4):912-920.
12. Merkel PA, Lo GH, Holbrook JT, et al; the Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142(8):620-626.
13. Hoffman GS, Cid MC, Hellmann DB, et al; International Network for the Study of Systemic Vasculitides. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309-1318.
14. Weyand CM. The Dunlop-Dottridge Lecture: The pathogenesis of giant cell arteritis. J Rheumatol. 2000;27(2):517-522.
15. Stone WJ. Comprehensive nursing approach to infliximab infusion therapy. J Infus Nurs. 2003;26(6):380-387.
16. Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol. 2002;81(1):26-32. Epub 2001 Dec 14.
17. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217-2224.
18. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996;98(12):2819-2826.
19. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352(4):351-361.
20. Smith K, Burns S, Jayne D. A prospective, open-label trial of B-cell depletion with rituximab in refractory systemic vasculitis. Kidney Blood Pressure Res. 2003;26(4):294-295.